Embecta (EMBC) Competitors $18.68 -0.13 (-0.69%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EMBC vs. PRCT, NVST, IRTC, NVCR, LIVN, WRBY, ENOV, TNDM, TMDX, and CNMDShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), TransMedics Group (TMDX), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Embecta vs. PROCEPT BioRobotics Envista iRhythm Technologies NovoCure LivaNova Warby Parker Enovis Tandem Diabetes Care TransMedics Group CONMED PROCEPT BioRobotics (NASDAQ:PRCT) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Do analysts prefer PRCT or EMBC? PROCEPT BioRobotics currently has a consensus target price of $97.86, suggesting a potential upside of 28.73%. Embecta has a consensus target price of $23.00, suggesting a potential upside of 23.13%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, equities research analysts plainly believe PROCEPT BioRobotics is more favorable than Embecta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Embecta 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to PRCT or EMBC? In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Embecta. MarketBeat recorded 7 mentions for PROCEPT BioRobotics and 4 mentions for Embecta. PROCEPT BioRobotics' average media sentiment score of 0.67 beat Embecta's score of 0.16 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, PRCT or EMBC? Embecta has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$136.19M29.13-$105.90M-$1.95-38.98Embecta$1.12B0.97$78.30M$1.3513.84 Is PRCT or EMBC more profitable? Embecta has a net margin of 6.97% compared to PROCEPT BioRobotics' net margin of -50.07%. Embecta's return on equity of -18.54% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-50.07% -38.57% -26.06% Embecta 6.97%-18.54%11.43% Which has more volatility & risk, PRCT or EMBC? PROCEPT BioRobotics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Does the MarketBeat Community favor PRCT or EMBC? PROCEPT BioRobotics received 37 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 67.86% of users gave PROCEPT BioRobotics an outperform vote while only 6.25% of users gave Embecta an outperform vote. CompanyUnderperformOutperformPROCEPT BioRoboticsOutperform Votes3867.86% Underperform Votes1832.14% EmbectaOutperform Votes16.25%Underperform Votes1593.75% Do institutionals & insiders have more ownership in PRCT or EMBC? 89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 0.4% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryPROCEPT BioRobotics and Embecta tied by winning 9 of the 18 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13B$4.54B$5.24B$8.95BDividend Yield3.08%47.30%5.13%4.04%P/E Ratio13.8426.2989.5417.34Price / Sales0.9758.321,255.2478.66Price / Cash5.8450.1443.8235.97Price / Book-1.467.795.324.79Net Income$78.30M$13.87M$122.69M$225.00M7 Day Performance-4.11%1.46%-0.16%1.52%1 Month Performance-6.22%11.95%3.75%4.68%1 Year Performance9.75%53.01%27.41%20.89% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta3.4649 of 5 stars$18.68-0.7%$23.00+23.1%+11.3%$1.13B$1.12B13.842,100Short Interest ↑Positive NewsPRCTPROCEPT BioRobotics2.8568 of 5 stars$82.72-4.8%$97.86+18.3%+64.0%$4.32B$199.84M-42.42430News CoverageNVSTEnvista3.4976 of 5 stars$19.12+2.9%$20.21+5.7%-14.0%$3.29B$2.50B-2.4612,700News CoverageIRTCiRhythm Technologies1.4303 of 5 stars$94.81-3.0%$108.45+14.4%-2.0%$2.97B$560.03M-19.511,790NVCRNovoCure3.2865 of 5 stars$26.67-2.8%$32.67+22.5%+110.7%$2.89B$577.74M-19.051,320Analyst ForecastAnalyst RevisionNews CoverageLIVNLivaNova3.5621 of 5 stars$47.46+1.7%$69.17+45.7%-4.2%$2.58B$1.15B113.002,900Analyst UpgradeWRBYWarby Parker2.3118 of 5 stars$24.97-1.4%$20.73-17.0%+89.3%$2.54B$742.53M-92.483,491Analyst ForecastShort Interest ↓News CoverageENOVEnovis3.0595 of 5 stars$45.34+1.3%$67.00+47.8%-18.9%$2.53B$2.00B-20.706,550Short Interest ↑News CoverageTNDMTandem Diabetes Care4.5351 of 5 stars$35.65-1.0%$53.81+50.9%+45.8%$2.34B$854.35M-18.472,400Positive NewsTMDXTransMedics Group4.2484 of 5 stars$64.71-6.0%$122.70+89.6%-27.3%$2.17B$401.09M68.84210News CoverageCNMDCONMED4.7192 of 5 stars$69.87+1.5%$79.80+14.2%-38.1%$2.16B$1.29B16.604,100 Related Companies and Tools Related Companies PRCT Alternatives NVST Alternatives IRTC Alternatives NVCR Alternatives LIVN Alternatives WRBY Alternatives ENOV Alternatives TNDM Alternatives TMDX Alternatives CNMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EMBC) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EMBC Stock Alerts